EGFR and lung carcinoma: The irreversible pan-ErbB inhibitor dacomitinib is currently in Phase III clinical trials for the treatment of patients with lung cancer and has shown promising activity in treating this malignancy (http://clinicaltrials.gov/ct2/show/NCT01000025).